Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research, Inc. is a Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group.
Price: $7.57 | Change: $-0.23 | %Change: -2.95%
Volume: 82,016 | Day High/Low: 8.00/7.35 | 52 Week High/Low: 8.33/1.66
View modes: 
2.5 stars


It would definitely be easier too get a vote from a competing company that made an attempt to buy-out / take-over Nuvo with the amount of disgruntled shareholders that still have shares here, more
3 stars


I agree although really what is the best real hard asset NRI has is Pennsaid 2% worldwide (ex USA).  With the move to go through phase 3 in Europe if Pennsaid gets over the counter approval by end more
3.5 stars


I think that coveage is just like what you said, as being "very close". I also believe now that  we have established a solid amount of volume above the 5 dollar level and the stock set a new 52 more
3 stars


Circassia has 190 million shares and about $250 million in cash and no revenues. It is burning through cash at about the rate of $75 million per year. Big difference is coverage by 5 analysts, more
5 stars


If Circassia with one Phase III testing product and several similar products in early testing phases, has a market cap of just under 1B CDN, then what is a realistic valuation for Nuvo 1) today?, more
2 stars

P 2 partner in Europe

Pennsaid 2% has been licensed to Paladin Labs Inc. for Canada, South Africa, Israel and Central and South America and to NovaMedica LLC for Russia and some of the Community of Independent States. more
2 stars

RE:Class Action by Long Term Shareholders?

Another of the lii folk  existing in dream land of 15 years ago. This stock was bankrupt when taken over by Magna former execs. They have done a great job considering the Great Recession of more
4 stars

Class Action by Long Term Shareholders?

Class Action by Long Term Shareholders? Holders of shares Higher than .20cents pre/split got the royal makeover by the so called P partner. That partner settled with the company to the tune of more
3 stars

RE:RE:RE:Intermediate Target

Hey Bigwig , Now that we finally have lift off(from the basement cellar) can you and Rock make an effort to ensure that management at Nuvo doesn't do anything stupid (like hiring a consulting more
3 stars

RE:RE:Intermediate Target

Actually, there arnt many canadian pharmaceuticals left on the TSX. Most have been taken over by the Seniors. The few that are left like TKM and CXR are trading on Nasdaq. They are very expensive more
3 stars

RE:Intermediate Target

That doesnt make much sense. Its worth that in cash. It just goes to show how oblivious TA is to changes in fundamentals.  rate and reply
4 stars

Intermediate Target

WebBroker has a new intermediate price target for Nuvo of $6.50 to $6.80 based on the chart upside breakout.  rate and reply
5 stars

RE:RE:new 52 week high

Like I said, New 52 week high reached today, just as I thought. Watch for this to continue easily to 6 dollars and higher next week. So much interest building daily, as I saw Laurention buying more
2.5 stars

RE:new 52 week high

nice....congrats all, playing for fun, a few shares when she hit sticker bids this past week or last week.  :) cheers, dave.  rate and reply
0 stars

RE:The Nasdaq Effect

has NRI applied for a Nasdaq listing?  rate and reply
5 stars

The Nasdaq Effect

Another example of a Nasdaq listing doubling the market cap is Cardiome (COM). $150 million market cap , with about $1 per share in cash and losing $4 million per quarter on sales of 2 drugs more
5 stars

new 52 week high

I fully expect to see this reach a new 52 week high tomorrow, based on the interest and the buying that is taking place. Lots of interest in this one is slowly gaining steam! Were 21 cents away more
2 stars


Yeah right. Your posting spoor doesn't include a single one.. Except this one. I have several..  rate and reply
3 stars


prepare for liftoff. wf10 p11 is not a proof of concept, we pretty much know the results already. our stock is slowly and quietly being accumulated. All we need is one or two institutions to come more
3.5 stars


I can't be bothered. I know, because I have and do own stocks that trade below cash including this one. Besides that, your analysis of the NRI selloff the other day was out to lunch and was more

Private Equity

Own a piece of our private equity marketplace: Limited to 50 members.

Click here to watch video 4

How to invest in private equity without writing a $1 million check.

Click here to watch video 3

Why the wealthy are 23x wealthier than the average investor.

Click here to watch video 2

Private Equity: Find out why it returned 16% p.a. for 10 years.

Click here to watch video 1